Drug Target Review

JUNE 5, 2023

It also supports the argument for developing ZW171 for the treatment of other MLSN-expressing solid tumours. What is the significance of ZW191 demonstrating strong responses in FRα-low expressing PDX models for the treatment of oncology indications with lower levels of FRα?

Treatment 100

Treatment Pharmacokinetics Drugs Cell Biology 100

The Pharma Data

JANUARY 26, 2021

Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. billion by 2027. (OTCQB: QBIO), announced today that the U.S.

FDA 40

FDA Treatment Small Molecule Drugs 40

The Pharma Data

APRIL 7, 2021

Yet as challenging as 2020 was, it also brought us –Sanofi and the pharmaceutical industry– closer to our purpose than at any other time in living memory ,” said Hudson. Leveraging R&D efforts to address crucial treatment gaps. The company is also committed to ecodesigning all its new products by 2025.

Vaccine 52

Vaccine Packaging Disease Treatment 52

Vial

FEBRUARY 29, 2024

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. A rise of clinical trial outsourcing due to cost management, globalization, and digitalization.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

Vial

DECEMBER 7, 2023

billion by 2027 , at a compound annual growth rate (CAGR) of 45.7% Although this staggering growth rate is related to the rise in adoption of cloud-based digital technology, as well as the need for more efficient drug discovery approaches, traditional methods continue to hold significant value in the pharmaceutical world.

Drugs 52

Drugs Clinical Trials Trials Treatment 52

FDA Law Blog: Biosimilars

JULY 24, 2023

Koblitz — Neither Jazz Pharmaceuticals nor Avadel CNS Pharmaceuticals has taken the battle of sodium oxybate—a drug approved to treat narcolepsy—lying down. After suing each other in patent litigation and Avadel’s suit against FDA challenging the Agency’s authority to compel patent certifications, it’s Jazz’s turn to sue FDA.

FDA 52

FDA Regulations Clinical Trials Drugs 52

Agency IQ

AUGUST 2, 2024

Positive August 2024 Eurneffy (epinephrine) Ars Pharmaceuticals Irl Limited Positive August 2024 MResvia (Respiratory Syncytial Virus mRNA vaccine) Moderna Biotech Spain S.L. Positive August 2024 Balversa (erdafitinib) Janssen-Cilag International N.V.

Regulations 40

Regulations Clinical Trials Production Trials 40